Swiss National Bank
HRTX icon

Swiss National Bank’s Heron Therapeutics HRTX Stock Holding History

Swiss National Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-256,600
Closed -$387K – 2633
2023
Q1 		$387K Buy
256,600
+8,800
+4% +$22K ﹤0.01% 2579
2022
Q4 		$620K Sell
247,800
-30,900
-11% -$99.5K ﹤0.01% 2525
2022
Q3 		$1.18M Buy
278,700
+38,000
+16% +$149K ﹤0.01% 2247
2022
Q2 		$672K Buy
240,700
+11,700
+5% +$47K ﹤0.01% 2535
2022
Q1 		$1.31M Buy
229,000
+15,300
+7% +$112K ﹤0.01% 2272
2021
Q4 		$1.95M Hold
213,700
– – ﹤0.01% 2076
2021
Q3 		$2.28M Buy
213,700
+22,300
+12% +$271K ﹤0.01% 1968
2021
Q2 		$2.97M Sell
191,400
-5,800
-3% -$92.3K ﹤0.01% 1840
2021
Q1 		$3.2M Buy
197,200
+2,000
+1% +$35.7K ﹤0.01% 1720
2020
Q4 		$4.13M Hold
195,200
– – ﹤0.01% 1476
2020
Q3 		$2.89M Buy
195,200
+4,200
+2% +$65.5K ﹤0.01% 1523
2020
Q2 		$2.81M Buy
191,000
+25,100
+15% +$412K ﹤0.01% 1514
2020
Q1 		$1.95M Buy
165,900
+5,100
+3% +$95.9K ﹤0.01% 1475
2019
Q4 		$3.78M Buy
160,800
+19,600
+14% +$434K ﹤0.01% 1334
2019
Q3 		$2.61M Buy
141,200
+3,000
+2% +$55.2K ﹤0.01% 1501
2019
Q2 		$2.57M Buy
138,200
+10,200
+8% +$204K ﹤0.01% 1543
2019
Q1 		$3.13M Buy
128,000
+4,300
+3% +$113K ﹤0.01% 1376
2018
Q4 		$3.21M Buy
123,700
+10,700
+9% +$294K ﹤0.01% 1257
2018
Q3 		$3.58M Buy
113,000
+12,700
+13% +$473K ﹤0.01% 1346
2018
Q2 		$3.9M Hold
100,300
– – ﹤0.01% 1260
2018
Q1 		$2.77M Buy
100,300
+1,800
+2% +$40.8K ﹤0.01% 1430
2017
Q4 		$1.78M Buy
98,500
+20,000
+25% +$326K ﹤0.01% 1711
2017
Q3 		$1.27M Hold
78,500
– – ﹤0.01% 1913
2017
Q2 		$1.09M Buy
78,500
+5,900
+8% +$85.5K ﹤0.01% 2003
2017
Q1 		$1.09M Buy
72,600
+20,700
+40% +$287K ﹤0.01% 1975
2016
Q4 		$680K Hold
51,900
– – ﹤0.01% 2251
2016
Q3 		$894K Hold
51,900
– – ﹤0.01% 2040
2016
Q2 		$937K Buy
51,900
+1,500
+3% +$29.3K ﹤0.01% 2004
2016
Q1 		$925K Buy
50,400
+9,200
+22% +$182K ﹤0.01% 1942
2015
Q4 		$1.1M Buy
+41,200
New +$1.1M ﹤0.01% 1756

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Swiss National Bank's HRTX Position: Q2 2023 in Review

Swiss National Bank sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 256,600 shares — an estimated $387K sold.

Swiss National Bank first reported a position in HRTX in Q4 2015 and held it in 30 quarters. The position peaked at $4.13M in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Swiss National Bank reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 256,600 Heron Therapeutics shares in Q2 2023, an estimated $387K.
  • Swiss National Bank first reported a position in Heron Therapeutics in Q4 2015 and held it in 30 quarters.
  • Swiss National Bank's Heron Therapeutics position peaked at $4.13M in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.